PETALING JAYA: The move to allow the registration of cannabidiol (CBD) products poses no concern as long as it passes due diligence checks by the National Pharmaceutical Regulatory Agency (NPRA), says the Malaysian Pharmacists Society (MPS).
The products, it said, would have to undergo a thorough review by NPRA before being allowed for medicinal use, noting that it would undergo the same process as other products meant for medicinal use.
